James P. Boylan - 13 Jun 2024 Form 4 Insider Report for Immunome Inc. (IMNM)

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IMNM	Stock option (right to buy)	Award	$0	+11,333		$0.000000	11,333	13 Jun 2024	Common Stock	11,333	$16.04	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Id	Content
F1	Mr. Boylan has agreed to receive and hold for the benefit of Enavate Sciences, LP, any securities granted to him for his service as a director on the Company's board of directors. As such, Mr. Boylan disclaims beneficial ownership of, and all right, title and interest in, the reported securities.
F2	The options vest in 4 quarterly installments, commencing from June 13, 2024 until the one year anniversary thereafter, occurring on the same day of each succeeding fiscal quarter, subject to continued service with the Company on each respective vesting date.